NCT03797391: A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase I of the study
Exclusions: Patients with symptomatic leptomeningeal or brain metastases

Comments are closed.

Up ↑